Charles River Laboratorie (NYSE: CRL) reported Q4 EPS of $0.81, $0.09 better than the analyst estimate of $0.72. Revenue for the quarter came in at $329.5 million versus the consensus estimate of $318.73 million.

Charles River Laboratorie sees FY2015 EPS of $3.55-$3.65, versus the consensus of $3.58.

For earnings history and earnings-related data on Charles River Laboratorie (CRL) click here.